Table 1. Indications for ERCP.
| Total (n = 804) | |
| Indication for ERCP | n (%) |
| Stenting for distal tumors | 213 (26.5) |
| CBD stones | 190 (23.6) |
| Cholangitis | 152 (18.9) |
| Biliary stent replacement | 62 (7.7) |
| Acute pancreatitis | 54 (6.7) |
| Perihilar cholangiocarcinoma | 28 (3.5) |
| Iatrogenic biliary leak/stricture | 23 (2.9) |
| Ampullary neoplasia | 22 (2.7) |
| Papillary stenosis of unknown origin | 13 (1.6) |
| Biliary stenosis in chronic pancreatitis | 9 (1.1) |
| Post-OLT biliary stenosis | 7 (0.9) |
| Recurrent pancreatitis in pancreas divisum | 6 (0.7) |
| Pancreatic stent replacement | 5 (0.6) |
| Main pancreatic duct stenosis or stone | 5 (0.6) |
| Hemobilia/papillary bleeding | 3 (0.4) |
| Other (Mirizzi’s syndrome, main pancreatic duct disruption, Recurrent pancreatitis, PSC, extrinsic neoplastic compression of CBD, peripapillary GIST) | 12 (1.5) |
ERCP – endoscopic retrograde cholangiopancreatography; CBD – common bile duct; OLT – orthotopic liver transplantation; PSC – primary sclerosing cholangitis; GIST – gastrointestinal stromal tumor.